The anti-COVID drug of the Defence Research and Development Organisation (DRDO) had been approved by the Drugs Controller General of India (DCGI) the previous week. Different healthcare professionals and people from the medical field have recently spoken up regarding this drug’s effectiveness. All these statements have proved the fact that the drug is beneficial against the pandemic.
The 2-deoxy-D-glucose (2-DG) received positive reviews from almost everyone. The trials performed with these doses have shown new results, which are again in favor of it. The drug is also assumed to be made available in the government healthcare systems very soon. Dr. Reddy’s laboratories are in charge of the bulk production of the drug, and they are trying hard to increase the rate of production of the 2-DG. Though all these are discussed, the drug’s price has not yet been fixed and is under debate. The company will soon let everyone know about the price at which the drug will be sold.
The reasons for the approval made last week:
The drug was found to be absolutely helpful for COVID patients. Different trials showed that the drug possesses an ability to cure patients of COVID approximately 2.5 days faster than they would have been fixed otherwise by the standard form of surgery. The drug can also accumulate in the cells where the viral attack had begun and stop the viral synthesis and energy production. All these lead to a reduction in the viral load, thus helping the patients to recover faster. The 2-DG also can reduce the patients’ dependence on the external supply of oxygen by maintaining the oxygen saturation level in the patients. Also, it has a more straightforward manufacturing process due to the use and availability of the components, assuring easier bulk production. The consumption of this drug is also easy since it comes in a sachet full of powder to be mixed in a glass full of water and drank.
New records about the drug:
All three phases of the trial had previously shown promising results. Recent findings mention the drug to be completely safe for use. Dr. Sudhir Chanda of the Institute of Nuclear Medicine and Allied Sciences (INMAS) has recently said that 42% of the patients administered with the drug have shown absolute freedom from oxygen dependence than the 31% from the group of patients not administered with the 2-DG. Dr. Chanda is a scientist and thus can be trusted.
Zeenews.india.com has rightfully recorded all these data. When out and available, this drug is considered to save more lives than the standard treatments are saving now.
